688319 欧林生物
交易中 12-08 11:06:01
资讯
新帖
简况
欧林生物：副总经理吴畏完成减持178500股
证券日报网 · 12-07 20:38
欧林生物：副总经理吴畏完成减持178500股
新股前瞻|破伤风疫苗龙头赴港，欧林生物(688319.SH)能否讲好IPO故事？
智通财经 · 12-07 17:50
新股前瞻|破伤风疫苗龙头赴港，欧林生物(688319.SH)能否讲好IPO故事？
欧林生物(688319.SH)补缴税款约420万元
智通财经 · 12-04
欧林生物(688319.SH)补缴税款约420万元
12月4日欧林生物涨13.78%，兴全社会价值三年持有混合基金重仓该股
证券之星 · 12-04
12月4日欧林生物涨13.78%，兴全社会价值三年持有混合基金重仓该股
欧林生物：11月28日高管吴畏减持股份合计10000股
证券之星 · 12-01
欧林生物：11月28日高管吴畏减持股份合计10000股
欧林生物向港交所主板递交上市申请；罗氏回应流感特效药需求上升 | 医药早参
每日经济新闻 · 11-27
欧林生物向港交所主板递交上市申请；罗氏回应流感特效药需求上升 | 医药早参
欧林生物(688319.SH)向香港联交所递交H股发行上市申请并刊发申请资料
智通财经 · 11-26
欧林生物(688319.SH)向香港联交所递交H股发行上市申请并刊发申请资料
欧林生物递表港交所，已实现吸附破伤风疫苗等三款产品的商业化
智通财经 · 11-26
欧林生物递表港交所，已实现吸附破伤风疫苗等三款产品的商业化
【新股IPO】欧林生物(688319)向港交所主板递交上市申请
金吾财讯 · 11-26
【新股IPO】欧林生物(688319)向港交所主板递交上市申请
每周股票复盘：欧林生物（688319）将召开2025年三季报说明会
证券之星 · 11-23
每周股票复盘：欧林生物（688319）将召开2025年三季报说明会
欧林生物（688319）披露将召开2025年第三季度业绩说明会，11月21日股价下跌5.66%
证券之星 · 11-21
欧林生物（688319）披露将召开2025年第三季度业绩说明会，11月21日股价下跌5.66%
11月21日欧林生物跌5.66%，兴全社会价值三年持有混合基金重仓该股
证券之星 · 11-21
11月21日欧林生物跌5.66%，兴全社会价值三年持有混合基金重仓该股
11月17日欧林生物跌6.65%，兴全社会价值三年持有混合基金重仓该股
证券之星 · 11-17
11月17日欧林生物跌6.65%，兴全社会价值三年持有混合基金重仓该股
每周股票复盘：欧林生物（688319）拟发行H股并回购注销22.47万股
证券之星 · 11-16
每周股票复盘：欧林生物（688319）拟发行H股并回购注销22.47万股
欧林生物（688319）披露拟发行H股并在香港联交所上市，11月14日股价上涨4.29%
证券之星 · 11-14
欧林生物（688319）披露拟发行H股并在香港联交所上市，11月14日股价上涨4.29%
每周股票复盘：欧林生物（688319）高管谭勇减持12.89万股完成计划
证券之星 · 11-09
每周股票复盘：欧林生物（688319）高管谭勇减持12.89万股完成计划
欧林生物（688319）披露拟发行H股并在港交所上市，11月06日股价上涨1.96%
证券之星 · 11-06
欧林生物（688319）披露拟发行H股并在港交所上市，11月06日股价上涨1.96%
欧林生物（688319）披露高级管理人员减持计划完成公告，11月03日股价下跌6.26%
证券之星 · 11-03
欧林生物（688319）披露高级管理人员减持计划完成公告，11月03日股价下跌6.26%
11月3日欧林生物跌6.26%，兴全社会价值三年持有混合基金重仓该股
证券之星 · 11-03
11月3日欧林生物跌6.26%，兴全社会价值三年持有混合基金重仓该股
每周股票复盘：欧林生物（688319）股东户数增56.42%
证券之星 · 11-02
每周股票复盘：欧林生物（688319）股东户数增56.42%
暂无数据
公司概况
公司名称：
成都欧林生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2021-06-08
主营业务：
成都欧林生物科技股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是吸附破伤风疫苗、Hib结合疫苗、AC结合疫苗。
发行价格：
9.88
{"stockData":{"symbol":"688319","market":"SH","secType":"STK","nameCN":"欧林生物","latestPrice":27.9,"timestamp":1765163161000,"preClose":27.39,"halted":0,"volume":5629279,"delay":0,"changeRate":0.0186,"floatShares":405000000,"shares":405999999,"eps":0.1582,"marketStatus":"交易中","change":0.51,"latestTime":"12-08 11:06:01","open":27.3,"high":28.56,"low":26.99,"amount":157000000,"amplitude":0.0573,"askPrice":27.9,"askSize":25,"bidPrice":27.89,"bidSize":27,"shortable":0,"etf":0,"ttmEps":0.1582,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1765164600000},"marketStatusCode":2,"adr":0,"adjPreClose":27.39,"symbolType":"stock_kcb","openAndCloseTimeList":[[1765157400000,1765164600000],[1765170000000,1765177200000]],"highLimit":30.13,"lowLimit":24.65,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":405933600,"isCdr":false,"pbRate":11.58,"roa":"--","peRate":176.359039,"roe":"5.02%","epsLYR":0.0512,"committee":0.382488,"marketValue":11326000000,"turnoverRate":0.0139,"status":0,"floatMarketCap":11311000000},"requestUrl":"/m/hq/s/688319/tweets","defaultTab":"tweets","newsList":[{"id":"2589706088","title":"欧林生物：副总经理吴畏完成减持178500股","url":"https://stock-news.laohu8.com/highlight/detail?id=2589706088","media":"证券日报网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589706088?lang=zh_cn&edition=full","pubTime":"2025-12-07 20:38","pubTimestamp":1765111080,"startTime":"0","endTime":"0","summary":"证券日报网讯12月5日晚间，欧林生物发布公告称，2025年9月29日至2025年12月5日期间，公司副总经理、董事会秘书吴畏先生通过集中竞价方式减持公司股份178，500股，占公司总股本的0.0440%，减持计划已实施完毕。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-07/doc-infzyxec2489232.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-07/doc-infzyxec2489232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688319"],"gpt_icon":0},{"id":"2589871929","title":"新股前瞻|破伤风疫苗龙头赴港，欧林生物(688319.SH)能否讲好IPO故事？","url":"https://stock-news.laohu8.com/highlight/detail?id=2589871929","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589871929?lang=zh_cn&edition=full","pubTime":"2025-12-07 17:50","pubTimestamp":1765101044,"startTime":"0","endTime":"0","summary":"自2021年6月于科创板上市以来，欧林生物持续受到市场关注。市场渠道方面，欧林生物的销售网络已覆盖中国30个省、直辖市及自治区。截至最新统计，中国共有七种获批的破伤风疫苗，市场呈现高度集中格局。其中，欧林生物占据领先地位，其吸附破伤风疫苗在2024年按批签发量计市场份额高达69.5%，武汉生物制品研究所则以30.5%的份额位居第二，两者合计占据绝大多数市场。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378492.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688319","BK0239","159645"],"gpt_icon":0},{"id":"2588376882","title":"欧林生物(688319.SH)补缴税款约420万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588376882","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588376882?lang=zh_cn&edition=full","pubTime":"2025-12-04 21:17","pubTimestamp":1764854225,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧林生物(688319.SH)发布公告，公司近期配合主管税务机关的工作对公司涉税事项进行了自查，经自查，公司本次预补缴企业所得税税款共计约420万元。截至公告披露日，公司已完成缴纳，主管税务机关未对该事项给予处罚。目前，相关事项尚在沟通与处理过程中，最终金额需税务机关进一步认定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377891.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688319","BK0239"],"gpt_icon":0},{"id":"2588098960","title":"12月4日欧林生物涨13.78%，兴全社会价值三年持有混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588098960","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588098960?lang=zh_cn&edition=full","pubTime":"2025-12-04 15:32","pubTimestamp":1764833562,"startTime":"0","endTime":"0","summary":"证券之星消息，12月4日欧林生物涨13.78%，收盘报27.99元，换手率3.33%，成交量13.51万手，成交额3.62亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为兴证全球基金的兴全社会价值三年持有混合。兴全社会价值三年持有混合目前规模为16.97亿元，最新净值2.0499，较上一交易日下跌1.07%，近一年上涨45.79%。该公募基金现任基金经理为谢治宇。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400018422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"gpt_icon":0},{"id":"2588724021","title":"欧林生物：11月28日高管吴畏减持股份合计10000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724021","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588724021?lang=zh_cn&edition=full","pubTime":"2025-12-01 20:03","pubTimestamp":1764590619,"startTime":"0","endTime":"0","summary":"证券之星消息，根据12月1日市场公开信息、上市公司公告及交易所披露数据整理，欧林生物最新董监高及相关人员股份变动情况：2025年11月28日公司高级管理人员吴畏共减持公司股份1.0万股，占公司总股本为0.0025%。欧林生物近半年内的董监高及核心技术人员增减持详情如下：欧林生物的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出255.75万，融资余额减少；融券净流入0.0，融券余额增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100030993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"gpt_icon":0},{"id":"2586892296","title":"欧林生物向港交所主板递交上市申请；罗氏回应流感特效药需求上升 | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2586892296","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586892296?lang=zh_cn&edition=full","pubTime":"2025-11-27 07:04","pubTimestamp":1764198298,"startTime":"0","endTime":"0","summary":"丨2025年11月27日星期四丨NO.1欧林生物向港交所主板递交上市申请11月26日，欧林生物发布公告，称公司于11月25日向香港联合交易所有限公司（简称“香港联交所”）递交了境外公开发行股份（H股）并在香港联交所主板上市的申请，并于同日在香港联交所网站刊登了本次发行上市的申请资料。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511273575830482.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511273575830482.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159938","BK0239","688319","BK1574","09939","BK1515","BK1161"],"gpt_icon":0},{"id":"2586400849","title":"欧林生物(688319.SH)向香港联交所递交H股发行上市申请并刊发申请资料","url":"https://stock-news.laohu8.com/highlight/detail?id=2586400849","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586400849?lang=zh_cn&edition=full","pubTime":"2025-11-26 07:54","pubTimestamp":1764114885,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧林生物(688319.SH)发布公告，公司于2025年11月25日向香港联合交易所有限公司(以下简称“香港联交所”)递交了境外公开发行股份(H股)并在香港联交所主板上市的申请，并于同日在香港联交所网站刊登了本次发行上市的申请资料。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373636.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688319","BK0239"],"gpt_icon":0},{"id":"2586407696","title":"欧林生物递表港交所，已实现吸附破伤风疫苗等三款产品的商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2586407696","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586407696?lang=zh_cn&edition=full","pubTime":"2025-11-26 07:08","pubTimestamp":1764112080,"startTime":"0","endTime":"0","summary":"招股书显示，欧林生物是一家面向全球、创新驱动的生物制药公司，致力于创新疫苗的研究、开发、生产及商业化。根据灼识咨询报告，欧林生物的吸附破伤风疫苗于往绩记录期间在中国保持领先的市场地位，按2022年至2024年批签发计，其市场份额超过80%。此外，欧林生物正在积极探索开发“超级细菌”联合疫苗，结合多种该等细菌靶点，以实现对多种抗药性感染的广泛防护。","market":"hk","thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373627.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688319"],"gpt_icon":0},{"id":"2586947706","title":"【新股IPO】欧林生物(688319)向港交所主板递交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2586947706","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586947706?lang=zh_cn&edition=full","pubTime":"2025-11-26 00:37","pubTimestamp":1764088642,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所11月25日披露，欧林生物 向港交所主板递交上市申请，中信证券为独家保荐人。公司是一家生物制药公司，实现三款产品的商业化：吸附破伤风疫苗、b型流感嗜血杆菌结合疫苗及A群C群脑膜炎球菌多糖结合疫苗。据灼识咨询报告，公司吸附破伤风疫苗于往绩记录期间在中国保持领先的市场地位，按2022年至2024年批签发计，其市场份额超过80%。截至2025年6月30日止六个月，公司收入为3.05亿元，公司权益股东应占期间利润1319.7万元。","market":"nz","thumbnail":"https://static.szfiu.com/news/20220324/MGRlNTRkNjg5NzY4YzMxZDdjZGQ5OGEzMzIxODkyNzUxMA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/MGRlNTRkNjg5NzY4YzMxZDdjZGQ5OGEzMzIxODkyNzUxMA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1970317","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688319","BK0239","HEXmain"],"gpt_icon":0},{"id":"2585644105","title":"每周股票复盘：欧林生物（688319）将召开2025年三季报说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2585644105","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585644105?lang=zh_cn&edition=full","pubTime":"2025-11-23 03:37","pubTimestamp":1763840231,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，欧林生物报收于21.51元，较上周的24.81元下跌13.3%。本周关注点公司公告汇总：成都欧林生物科技股份有限公司将于2025年12月01日召开2025年第三季度业绩说明会。公司公告汇总成都欧林生物科技股份有限公司关于召开2025年第三季度业绩说明会的公告成都欧林生物科技股份有限公司将于2025年12月01日上午10:00-11:00通过上证路演中心网络互动方式召开2025年第三季度业绩说明会，介绍公司2025年前三季度经营成果、财务状况，并回答投资者提问。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000935.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"gpt_icon":0},{"id":"2585868141","title":"欧林生物（688319）披露将召开2025年第三季度业绩说明会，11月21日股价下跌5.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585868141","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585868141?lang=zh_cn&edition=full","pubTime":"2025-11-21 22:39","pubTimestamp":1763735977,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，欧林生物报收于21.51元，较前一交易日下跌5.66%，最新总市值为87.32亿元。近日，成都欧林生物科技股份有限公司发布公告，宣布将于2025年12月1日上午10:00至11:00通过上证路演中心网络互动方式召开2025年第三季度业绩说明会。公司将介绍2025年前三季度的经营成果及财务状况，并回答投资者提问。投资者可于2025年11月24日至11月28日16:00前通过上证路演中心或公司邮箱ir@olymvax.com提前提问。说明会结束后，会议情况可通过上证路演中心查看。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100040598.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"gpt_icon":0},{"id":"2585190891","title":"11月21日欧林生物跌5.66%，兴全社会价值三年持有混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2585190891","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585190891?lang=zh_cn&edition=full","pubTime":"2025-11-21 15:46","pubTimestamp":1763711168,"startTime":"0","endTime":"0","summary":"证券之星消息，11月21日欧林生物跌5.66%创60日新低，收盘报21.51元，换手率1.08%，成交量4.37万手，成交额9567.47万元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为兴证全球基金的兴全社会价值三年持有混合。兴全社会价值三年持有混合目前规模为16.97亿元，最新净值2.0547，较上一交易日下跌0.45%，近一年上涨47.52%。该公募基金现任基金经理为谢治宇。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100018704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"gpt_icon":0},{"id":"2584435926","title":"11月17日欧林生物跌6.65%，兴全社会价值三年持有混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2584435926","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584435926?lang=zh_cn&edition=full","pubTime":"2025-11-17 16:31","pubTimestamp":1763368270,"startTime":"0","endTime":"0","summary":"证券之星消息，11月17日欧林生物跌6.65%，收盘报23.16元，换手率2.17%，成交量8.8万手，成交额2.06亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为兴证全球基金的兴全社会价值三年持有混合。兴全社会价值三年持有混合目前规模为16.97亿元，最新净值2.0863，较上一交易日下跌1.82%，近一年上涨50.12%。该公募基金现任基金经理为谢治宇。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700020854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"gpt_icon":0},{"id":"2583654336","title":"每周股票复盘：欧林生物（688319）拟发行H股并回购注销22.47万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2583654336","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583654336?lang=zh_cn&edition=full","pubTime":"2025-11-16 04:21","pubTimestamp":1763238070,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，欧林生物报收于24.81元，较上周的22.93元上涨8.2%。本周关注点公司公告汇总：欧林生物拟发行H股并在香港联交所上市，相关议案已获股东会通过。公司公告汇总：公司决定回购注销224,700股限制性股票，总股本将减少至405,708,900股。会议审议通过了关于回购注销2023年限制性股票激励计划部分股票、变更注册资本并修订公司章程、发行H股并在香港联交所上市等14项议案，各项议案均已获得有效表决通过。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001206.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"gpt_icon":0},{"id":"2583502733","title":"欧林生物（688319）披露拟发行H股并在香港联交所上市，11月14日股价上涨4.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583502733","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583502733?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:49","pubTimestamp":1763131757,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，欧林生物报收于24.81元，较前一交易日上涨4.29%，最新总市值为100.71亿元。根据公司近日发布的公告，成都欧林生物科技股份有限公司于2025年11月14日召开2025年第二次临时股东会，审议通过了关于发行境外上市股份（H股）并在香港联合交易所上市的议案。同时，会议还通过了公司转为境外募集股份并上市的股份有限公司、H股募集资金使用计划、授权董事会办理H股发行上市相关事宜等多项相关议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400042156.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"gpt_icon":0},{"id":"2582686127","title":"每周股票复盘：欧林生物（688319）高管谭勇减持12.89万股完成计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2582686127","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582686127?lang=zh_cn&edition=full","pubTime":"2025-11-09 04:20","pubTimestamp":1762633221,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，欧林生物报收于22.93元，较上周的25.09元下跌8.61%。本周，欧林生物11月3日盘中最高价报25.36元。本周关注点股本股东变化：高管谭勇减持128,860股，占总股本0.0317%，计划已完成。公司公告汇总：欧林生物拟发行H股上市，发行规模不超过发行后总股本的25%。股本股东变化2025年10月31日，公司高级管理人员谭勇减持6.94万股，占公司总股本0.0171%。期间股价上涨6.72%，10月31日收盘价为25.09元。减持后持股442,580股，占总股本0.1090%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"gpt_icon":0},{"id":"2581309124","title":"欧林生物（688319）披露拟发行H股并在港交所上市，11月06日股价上涨1.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581309124","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581309124?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:22","pubTimestamp":1762438943,"startTime":"0","endTime":"0","summary":"截至2025年11月6日收盘，欧林生物报收于22.93元，较前一交易日上涨1.96%，最新总市值为93.08亿元。该股当日开盘22.49元，最高23.18元，最低22.49元，成交额达1.02亿元，换手率为1.11%。根据公司近日发布的《成都欧林生物科技股份有限公司2025年第二次临时股东会会议资料》，欧林生物拟发行境外上市股份（H股）并在香港联合交易所上市，发行规模不超过发行后总股本的25%，并授予超额配售权。上述事项尚需提交股东会审议批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600038205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","HEXmain","688319"],"gpt_icon":0},{"id":"2580211615","title":"欧林生物（688319）披露高级管理人员减持计划完成公告，11月03日股价下跌6.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580211615","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580211615?lang=zh_cn&edition=full","pubTime":"2025-11-03 22:23","pubTimestamp":1762179787,"startTime":"0","endTime":"0","summary":"截至2025年11月3日收盘，欧林生物报收于23.52元，较前一交易日下跌6.26%，最新总市值为95.48亿元。近日，成都欧林生物科技股份有限公司发布高级管理人员减持计划完成暨减持股份结果公告。本次减持计划已实施完毕，减持数量与此前披露的计划一致。减持完成后，谭勇持有公司股份442,580股，占总股本的0.1090%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300035953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"gpt_icon":0},{"id":"2580526209","title":"11月3日欧林生物跌6.26%，兴全社会价值三年持有混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2580526209","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580526209?lang=zh_cn&edition=full","pubTime":"2025-11-03 16:32","pubTimestamp":1762158765,"startTime":"0","endTime":"0","summary":"证券之星消息，11月3日欧林生物跌6.26%，收盘报23.52元，换手率3.13%，成交量12.69万手，成交额3.02亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为兴证全球基金的兴全社会价值三年持有混合。兴全社会价值三年持有混合目前规模为16.97亿元，最新净值2.1056，较上一交易日下跌1.11%，近一年上涨55.03%。该公募基金现任基金经理为谢治宇。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300021636.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"gpt_icon":0},{"id":"2580743334","title":"每周股票复盘：欧林生物（688319）股东户数增56.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580743334","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580743334?lang=zh_cn&edition=full","pubTime":"2025-11-02 05:42","pubTimestamp":1762033336,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，欧林生物报收于25.09元，较上周的23.04元上涨8.9%。交易信息汇总10月31日，欧林生物发生16笔折价21.88%的大宗交易，合计成交7841.32万元。股本股东变化股东户数变动截至2025年9月30日，欧林生物股东户数为1.02万户，较6月30日增加3679.0户，增幅56.42%。控股股东上海武山生物技术有限公司已完成减持，通过集中竞价和大宗交易累计减持12,178,008股，占总股本3.00%，减持后持股比例由17.83%降至14.83%，一致行动人合计持股比例由27.92%降至26.23%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765163190100,"stockEarnings":[{"period":"1week","weight":0.0616},{"period":"1month","weight":0.2179},{"period":"3month","weight":-0.0218},{"period":"6month","weight":0.5388},{"period":"1year","weight":1.3094},{"period":"ytd","weight":1.584}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0167},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.1529},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1644}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"成都欧林生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10200人(较上一季度增加56.42%)","perCapita":"39746股","listingDate":"2021-06-08","address":"四川省成都市郫都区高新区天欣路99号","registeredCapital":"40593万元","survey":" 成都欧林生物科技股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是吸附破伤风疫苗、Hib结合疫苗、AC结合疫苗。","listedPrice":9.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧林生物(688319)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧林生物(688319)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧林生物,688319,欧林生物股票,欧林生物股票老虎,欧林生物股票老虎国际,欧林生物行情,欧林生物股票行情,欧林生物股价,欧林生物股市,欧林生物股票价格,欧林生物股票交易,欧林生物股票购买,欧林生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧林生物(688319)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧林生物(688319)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}